MatRx founders have more than 20 years of foundational research at leading New York hospitals, supported by NIH grants and private foundations.
Between 2005 and 2011, they conducted preclinical studies demonstrating positive impact of Hyaluronan in emphysema-induced mice.
Two human clinical trials were conducted in 2017 and 2021 further supporting that Hyaluronan is effective and safe as a COPD treatment.
MatRx has been granted treatment and biomarker patents for Hyaluronan and has patents filed in US and Europe.
MatRx is seeking $8 million in funding to conduct a Phase 2 clinical trial of up to 80 patients to further validate Hyaluronan's efficacy and safety.
MatRx Proprietary and Confidential
This patent protects MatRx's therapeutic approach for treating COPD by targeting the underlying cause of lung tissue degradation.​
This patent, licensed from Columbia University, enables MatRx to identify and develop promising compounds for COPD treatment.
The US Department of Health & Human Services has granted Hyaluronan Orphan Drug Status for the treatment of emphysema due to Alpha-1 antitrypsin deficiency.
*Patents available on demand
This patent protects MatRx's innovative approach to treating COPD by targeting the underlying cause of lung tissue degradation.
This patent expands MatRx's intellectual property protection, ensuring global coverage for its revolutionary COPD treatment.
MatRx Proprietary and Confidential
MatRx Therapeutics is led by an exceptional team of experienced researchers and clinicians who have dedicated their careers to unlocking new treatments for COPD. The founders, Dr. Gerard M. Turino and lead researcher Dr. Jerome O. Cantor, bring over 30 years of foundational research in lung disease and innovative approaches to addressing the underlying causes of COPD.
- Professor of Medicine at Mount Sinai Icahn School
- Senior Physician at Mount Sinai St. Luke's/Roosevelt Hospital
- John H. Keating Professor Emeritus at Columbia
- Founder of the James P. Mara Center for Lung Disease
- Former President of the American Thoracic Society
- Founding member of the Alpha-1 Foundation
- Co-founded the COPD Foundation, remains on Board
- Founded MatRx Therapeutics in 2015, CEO and Chairman
MatRx Proprietary & Confidential
- Distinguished medical professional and researcher
- Professor at St. John's University, expert in pulmonary pathophysiology
- Vice President, Ines Mandl Research Foundation
- Recipient of grants and awards for pulmonary pathophysiology research
- President of MatRx Therapeutics, led COPD treatment research
MatRx proprietary and confidential
MatRx Therapeutics has successfully completed animal and two Phase 1 human trials and is now seeking $8 million to advance its aerosolized hyaluronan (HA) therapy for COPD into a Phase 2 clinical trial to further validate the therapy in larger human sample size, targeted to begin in 2025.
To fund Phase 2 clinical trial
Projected start date
MatRx Proprietary & Confidential
2023
2033
The COPD global market is projected to grow significantly. New drug approvals drive growth, including Sanofi/Regeneron’s Dupixent. Additional pipeline agents are expected to be approved during the forecast period, further expanding the market.
MatRx proprietary and confidential
•The only treatment that addresses the underlying cause of COPD
•Easy to administer – aerosolized treatment without clinical difficulty
•Inexpensive to manufacture
•Anti-inflammatory and safe
•Can be combined with other aerosolized treatments such as bronchodilators
•Studies have shown beneficial results in as little as 2 weeks
MatRx proprietary and confidential
Thank you for your time and consideration. We appreciate your interest in MatRx Therapeutics and our innovative approach to COPD treatment. MatRx is excited to move forward with our Phase 2 clinical trial and believes our therapy has the potential to significantly impact the lives of COPD patients.
This is an exceptional opportunity for investors to be part of a groundbreaking advancement in COPD care, and we would be thrilled to have you onboard.
We welcome any questions or feedback you may have.
Contact: James Turino james@tkanyc.com
Pioneering innovative hyaluronan-based therapies to treat the underlying cause of Chronic Obstructive Pulmonary Disease (COPD).